{"schema_version":"1","generated_at":"2026-11-20T11:35:17.165Z","data_as_of":null,"url":"https://www.findmykol.com/kol/shaker-dakhil","json_url":"https://www.findmykol.com/kol/shaker-dakhil/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"shaker-dakhil","name":"Shaker Dakhil","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Cancer Center of Kansas","institution_url":"https://www.findmykol.com/institution/cancer-center-of-kansas","city":"Wichita","state":"KS","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Shaker Dakhil is an Oncology physician affiliated with Cancer Center of Kansas. OpenAlex indexes 427 publications with 37,397 citations (h-index 81). By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":427,"cited_by_count":37397,"h_index":81,"latest_activity_year":2025,"citation_standing":{"top_percent":5,"cohort":"Hematology / Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"payments":{"company_count":113,"program_years":{"first":2021,"last":null},"rows_total":359,"shown":3,"withheld":356,"rows":[{"payer":"Novartis","program_year":2025,"amount_usd":1243392.29,"payment_count":9},{"payer":"Amgen","program_year":2025,"amount_usd":137570.72,"payment_count":3},{"payer":"BeiGene","program_year":2025,"amount_usd":38239.81,"payment_count":11}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":13,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":39.9,"classes_total":17,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":18.8,"drugs":[{"name":"Pembrolizumab","share_pct":55.3},{"name":"Nivolumab","share_pct":44.7}],"max_beneficiaries":40},{"class":"Platinum-based Drug","setting":"administered","share_pct":6.3,"drugs":[{"name":"Oxaliplatin","share_pct":96.8},{"name":"Carboplatin","share_pct":3.2}],"max_beneficiaries":43}]},{"area":"Blood & clotting","share_pct":28.1,"classes_total":2,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":20.8,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":41},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":7.3,"drugs":[{"name":"Darbepoetin alfa","share_pct":58.2},{"name":"Epoetin alfa","share_pct":41.8}],"max_beneficiaries":26}]},{"area":"Metabolism & gastrointestinal","share_pct":17.1,"classes_total":6,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":9.5,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":103},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":7.1,"drugs":[{"name":"Granisetron","share_pct":81.9},{"name":"Ondansetron hydrochloride","share_pct":13.8},{"name":"Palonosetron hcl","share_pct":4},{"name":"Ondansetron Hcl","share_pct":0.2},{"name":"Ondansetron Odt","share_pct":0.2}],"max_beneficiaries":84}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2001,"last":2018},"rows_total":22,"shown":3,"withheld":19,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"UG1CA189808","title":"National Community Oncology Research Project","fiscal_year":2018,"amount_usd":"1527000","organization":"VIA CHRISTI REGIONAL MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/UG1CA189808"},{"project":"UG1CA189808","title":"National Community Oncology Research Project","fiscal_year":2017,"amount_usd":"1835874","organization":"VIA CHRISTI REGIONAL MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/UG1CA189808"},{"project":"UG1CA189808","title":"National Community Oncology Research Project","fiscal_year":2016,"amount_usd":"1612500","organization":"VIA CHRISTI REGIONAL MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/UG1CA189808"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2022.09.159","status":"verified"},{"title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","year":2021,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.20.02212","status":"verified"},{"title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","year":2020,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(19)30863-0","status":"verified"},{"title":"Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","year":2020,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(20)30539-8","status":"verified"},{"title":"Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","year":2019,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(19)32222-6","status":"verified"}],"source":"works"},"similar":[{"name":"Bassam Mattar","slug":"bassam-mattar","institution":"Cancer Center of Kansas","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/bassam-mattar","json_url":"https://www.findmykol.com/kol/bassam-mattar/profile.json"},{"name":"Christopher Dakhil","slug":"christopher-dakhil","institution":"Cancer Center of Kansas","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christopher-dakhil","json_url":"https://www.findmykol.com/kol/christopher-dakhil/profile.json"},{"name":"Jeremy Deutsch","slug":"jeremy-deutsch","institution":"Cancer Center of Kansas","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jeremy-deutsch","json_url":"https://www.findmykol.com/kol/jeremy-deutsch/profile.json"},{"name":"Dennis Moore","slug":"dennis-moore","institution":"Cancer Center of Kansas","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/dennis-moore","json_url":"https://www.findmykol.com/kol/dennis-moore/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":356,"funding":19,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}